What is Selank? Nootropic Peptide for Anxiety & Cognition

Selank is a seven-amino-acid tuftsin analogue designed to provide anxiolysis without sedative side effects. In a clinical study of patients with generalized anxiety disorder (GAD) and neurasthenia, Selank's anxiolytic action matched that of medazepam (a benzodiazepine) while adding anti-asthenic/psychostimulant benefits.

Selank affects GABAergic and monoaminergic signaling in ways that reduce anxiety while maintaining cognition. Transcriptomic analysis shows broad regulation of GABAergic genes after Selank administration — interpreted as indirect GABAergic modulation (not classical benzodiazepine receptor agonism). Additionally, BDNF — a critical neuroplasticity factor — increases in the hippocampus after intranasal Selank.

Selank inhibits enkephalin-degrading enzymes in human serum (enkephalinases), extending endogenous enkephalin tone associated with stress relief and analgesia. This mechanism complements its anxiolytic profile.

As a tuftsin analogue, Selank shows immunomodulatory effects — altered cytokine/chemokine gene expression (~34 targets in mouse spleen) and normalization of inflammatory signals under stress. This may explain reports of improved stress resilience.

Beyond anxiety, Selank showed antiviral activity against influenza A/H3N2 virus in vitro and in vivo, with stronger action through preventive administration before exposure — a finding that strengthens the 'stress-immune' narrative.

Both Selank and Semax are Russian nootropic peptides. Selank focuses on anxiolysis through GABAergic/enkephalinergic mechanisms, while Semax (an ACTH analogue) focuses on cognitive enhancement through BDNF and melanocortin receptors. Many researchers study them in combination.